Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 13/8/2019
SIETES contiene 92794 citas

 
 
 1 a 20 de 78 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]
2. Cita con resumen
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016;315:2424-34. [Ref.ID 100458]
3. Cita con resumen
McCarthy M. US needs $1.1bn to treat opioid addiction. BMJ 2016;352:i694. [Ref.ID 100047]
4. Cita con resumen
Anónimo. Dangers de l'anorexigène Mysimba: mobilisation citoyenne bienvenue. Prescrire 2015;35:305. [Ref.ID 99129]
5. Cita con resumen
Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]
6.
Anónimo. Diet, drugs, and surgery for weight loss. Med Lett Drugs Ther 2015;57:21-8. [Ref.ID 98856]
7. Cita con resumen
Anónimo. FDA approves weight-management drug Contrave. U.S. Food and Drug Administration 2014:10 de septiembre. [Ref.ID 97890]
8. Cita con resumen
Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass E, Rowe CJ, Garbutt JC. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014;311:1889-900. [Ref.ID 97596]
9. Cita con resumen
Spence D. Bad medicine: nalmefene in alcohol misuse. BMJ 2014;348:g1531. [Ref.ID 97333]
10. Cita con resumen
Anónimo. Nalméfène. Prescrire 2014;34:6-9. [Ref.ID 97005]
11. Cita con resumen
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2013;311:74-86. [Ref.ID 96313]
12.Tiene citas relacionadas
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-13. [Ref.ID 90683]
13.Tiene citas relacionadas
Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet 2011;377:1468-70. [Ref.ID 90674]
14.Enlace a cita original
Karila L, Weinstein A, Aubin H-J, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 2010;69:578-92. [Ref.ID 88517]
15. Cita con resumen
Anónimo. A morphine/naltrexone combination (Embeda) for pain. Med Lett Drugs Ther 2010;52:22-3. [Ref.ID 88306]
17.
Schuckit MA. Alcohol-use disorders. Lancet 2009;373:492-501. [Ref.ID 85216]
18. Cita con resumen
Plieth J. Obesity: what next after the CB1 antagonists' failure?. Scrip 2008;3411/3412:44-7. [Ref.ID 84469]
20.Tiene citas relacionadas
Hall WD, Mattick RP. Oral substitution treatments for opioid dependence. Lancet 2008;371:2150-1. [Ref.ID 83424]
Seleccionar todas
 
 1 a 20 de 78 siguiente >>